Search Log In

fig1

From:  Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases
Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases

Figure 1. Dosing schedule of the doxorubicin (DOX) + zoledronic acid (ZOL) group

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)
Navigation
Follow Us
Navigation

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/
partners@oaepublish.com Company Contact Us
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2024 OAE Publishing Inc., except certain content provided by third parties